MiniMed Smart MDI Alerts Improve Glucose Outcomes in Type 1 Diabetes…

Event summary

MiniMed's six-month randomized trial showed that higher responders to Smart MDI alerts achieved 8.1 percentage points more Time in Range and 0.6 percentage points lower HbA1c.
The study involved 143 people with type 1 diabetes and HbA1c above 8%.
Real-world analysis of over 5,500 users found a 9.4 percentage-point difference in Time in Range between higher and lower responders.
The Smart MDI system met the primary endpoint and was non-inferior to multiple daily injections plus continuous glucose monitoring in glycemic outcomes.
No severe hypoglycemia or diabetic ketoacidosis events were reported in the Smart MDI arm during the study.

The big picture

MiniMed's findings highlight the critical role of actionable alerts in improving diabetes management outcomes. The Smart MDI system addresses the mental burden of multiple daily injections by integrating real-time glucose data, dose calculations, and missed-dose alerts into a single app. This innovation is particularly significant as pump therapy remains recommended but not universally accessible or preferred. The study's results could influence the broader adoption of smart insulin pen systems in diabetes care.

What we're watching

Adoption Dynamics: How MiniMed will scale the adoption of the Smart MDI system among type 1 diabetes patients who prefer multiple daily injections over pump therapy.
Outcome Validation: Whether the improved glucose outcomes from higher alert response rates can be sustained over longer periods and across broader patient populations.
Competitive Positioning: The pace at which MiniMed can differentiate its Smart MDI system from traditional insulin pens and other connected pens in the market.